Bisc Therapeutics develops first-in-class therapies that protect retinal health and prevent vision loss in patients with degenerative eye diseases. The company's Bax inhibitor technology halts retinal cell death at its core, targeting conditions such as age-related macular degeneration, glaucoma, and inherited retinal disorders. Its patient- and physician-friendly delivery approach aims to improve outcomes for millions at risk of blindness.
Funding
Funding not disclosed
Founders
Product
Problem
Millions of patients face progressive, irreversible vision loss due to retinal degenerative diseases such as age-related macular degeneration, glaucoma, and inherited retinal disorders. Current treatments often fail to halt the underlying cellular death that drives these conditions, leaving patients with limited options to preserve sight.
Solution
Bisc Therapeutics is developing first-in-class therapies designed to preserve vision by targeting the root cause of retinal degeneration. Its proprietary Bax inhibitor technology protects retinal cells by halting cell death at its core, offering a mechanism distinct from conventional approaches. The therapy is being designed for a range of retinal conditions, with a patient- and physician-friendly delivery format intended to support practical clinical use. This approach aims to slow disease progression and maintain visual function, with the potential to improve long-term quality of life for those at risk.
Target Audience
Primary customers are ophthalmologists, retina specialists, and healthcare providers treating patients with retinal degenerative diseases, as well as the patient populations affected by these progressive conditions.
Features
- Bax inhibitor technology that directly blocks retinal cell death, a novel mechanism for neuroprotection
- Platform applicable to multiple degenerative retinal diseases, including age-related macular degeneration, glaucoma, and inherited retinal disorders
- Focus on best-in-class science combined with a delivery approach designed for ease of use by patients and physicians
- First-in-class positioning with potential to address significant unmet need in vision preservation